PEDIATRICS Vol. 26 No. 3 September 1960, pp. 347-350
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schulman, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulman, I.

EXPERIMENTAL CARCINOGENESIS WITH IRON-DEXTRAN

Irving Schulman M.D.1

1 Children's Memorial Hospital, 707 Fullerton Ave., Chicago 14, Illinois

Two Articles in this issue of Pediatrics report on the use of an iron-dextran complex (Imferon), a preparation which, on April 25, 1960, was withdrawn from the American market. This action was taken by the distributor, Lakeside Laboratories, upon recommendation of the Food and Drug Administration and followed publication of experiments which demonstrated the induction of sarcomas in mice and rats at the sites of repeated injections of the drug. In view of the extensive clinical use of Imferon in recent years it seems appropriate to review critically the evidence for the possible carcinogenicity of the preparation and the justification for its removal from the market.